Protein-Targeted Degradation Agents Based on Natural Products

Protein-Targeted Degradation Agents Based on Natural Products

Natural products are an important source of drug lead compounds, and natural products with significant biological activity are constantly being discovered and used in clinical practice. At present, natural products play an important role in the targeted therapy of cancer, cardiovascular and cerebrov...

Full description

Bibliographic Details
Main Authors:	Yan Li, Yi Jia, Xiaolin Wang, Hai Shang, Yu Tian
Format:	Article
Language:	English
Published:	MDPI AG 2022-12-01
Series:	Pharmaceuticals
Subjects:	natural products molecular-targeted drugs targeted protein degradation agents PROTAC molecular glue
Online Access:	https://www.mdpi.com/1424-8247/16/1/46

Similar Items

Key Considerations in Targeted Protein Degradation Drug Discovery and Development
by: Liena Qin, et al.
Published: (2022-08-01)

Central Nervous System Targeted Protein Degraders
by: Bedwyr ab Ion Thomas, et al.
Published: (2023-07-01)

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
by: Corentin Bouvier, et al.
Published: (2024-03-01)

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
by: Xiaopeng Peng, et al.
Published: (2024-02-01)

Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
by: Sandra Kuemper, et al.
Published: (2024-04-01)

Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules
by: Alexandré Delport, et al.
Published: (2019-09-01)

Recent Advances in PROTACs for Drug Targeted Protein Research
by: Tingting Yao, et al.
Published: (2022-09-01)

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
by: Siqi Wang, et al.
Published: (2024-01-01)

Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
by: Lu Lv, et al.
Published: (2020-08-01)

Discovery of E3 Ligase Ligands for Target Protein Degradation
by: Jaeseok Lee, et al.
Published: (2022-10-01)

News from DMCCB – Targeted Protein Degradation
by: Georg Jaeschke
Published: (2018-12-01)

Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
by: Yungang Wang, et al.
Published: (2020-08-01)

Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
by: Sandeep Rana, et al.
Published: (2021-11-01)

Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation
by: Guliang Yang, et al.
Published: (2022-03-01)

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
by: Chao Wang, et al.
Published: (2022-12-01)

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments
by: Lanshu Xiao, et al.
Published: (2023-12-01)

Targeted Protein Degradation: Principles and Applications of the Proteasome
by: Yosup Kim, et al.
Published: (2023-07-01)

Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
by: Qiao-Hong Chen, et al.
Published: (2024-02-01)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
by: Rui Li, et al.
Published: (2022-12-01)

Current Status of Oligonucleotide-Based Protein Degraders
by: Po-Chang Shih, et al.
Published: (2023-02-01)

From classic medicinal chemistry to state‐of‐the‐art interdisciplinary medicine: Recent advances in proteolysis‐targeting chimeras technology
by: Xuyang Zhao, et al.
Published: (2023-04-01)

Targeted protein degradation for the treatment of Parkinson’s disease: Advances and future perspective
by: Roshanak Amirian, et al.
Published: (2023-10-01)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
by: Soonsil Hyun, et al.
Published: (2021-11-01)

Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality
by: Yang Zhou, et al.
Published: (2023-08-01)

Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity
by: Jinmin Miao, et al.
Published: (2023-10-01)

The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
by: Bernat Coll-Martínez, et al.
Published: (2020-12-01)

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
by: Caterina Mancarella, et al.
Published: (2023-11-01)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
by: Minoru Ishikawa, et al.
Published: (2020-04-01)

Targeted Protein Degradation Systems: Controlling Protein Stability Using E3 Ubiquitin Ligases in Eukaryotic Species
by: Yoshitaka Ogawa, et al.
Published: (2024-01-01)

PROTACs targeting epigenetic proteins
by: Chao Zhang, et al.
Published: (2023-12-01)

Recent Advances in PROTAC-Based Antiviral Strategies
by: Haleema Ahmad, et al.
Published: (2023-01-01)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
by: Sinan Ma, et al.
Published: (2022-07-01)

Recent Advances in Optically Controlled PROTAC
by: Muzi Ouyang, et al.
Published: (2023-11-01)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
by: Xinyi Li, et al.
Published: (2022-04-01)

Targeting Protein Kinases Degradation by PROTACs
by: Fei Yu, et al.
Published: (2021-06-01)

Linkers as Game-changers in PROTAC Technology: Emphasizing General Trends in PROTAC Pharmacokinetics for their Rational Design
by: Carlotta Cecchini, et al.
Published: (2022-04-01)

Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System
by: Sridhar Radhakrishnan, et al.
Published: (2022-11-01)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
by: Yujeong Moon, et al.
Published: (2023-01-01)

PROTAC vaccine: A new way to live attenuated vaccines
by: Zhen Li, et al.
Published: (2022-10-01)

TACkling Cancer by Targeting Selective Protein Degradation
by: María del Mar Noblejas-López, et al.
Published: (2023-10-01)